Sancilio Pharma Files for IPO

By Chris Lange Published Sep 1, 9:55AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Sancilio Pharmaceuticals Co. Inc. has filed an S-1 form with the Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No terms were given in the filing, but the offering is valued up to $86.25 million. The company intends to list on the Nasdaq Capital Market under the symbol SPCI.

The underwriters for the offering are UBS, Piper Jaffray, JMP Securities and FBR.

This is a fully integrated specialty pharmaceutical company focused on developing and, in the future, commercializing products based on its proprietary Advanced Lipid Technologies (ALT) platform. Sancilio intends to utilize its current manufacturing facility to manufacture our proprietary product candidates, if approved.

ALT is designed to enhance the bioavailability, reduce the food effect and improve the efficacy of lipids and lipophilic active pharmaceutical ingredients (APIs). Lipids are small hydrophobic or amphipathic molecules, including fatty acids (such as omega-3 fatty acids and omega-6 fatty acids), steroids, hormones and fat-soluble vitamins (such as vitamins A, D, E and K).

The business model is to apply the ALT platform to lipids or lipophilic APIs to create unique product candidates that address the disorders and diseases that result from imbalances of lipids in the body. In addition to Sancilio’s primary focus of developing proprietary products using the ALT platform, the company makes use of and license rights to the proprietary ALT platform and other technologies to third parties as part of the development and manufacture of lipophilic API-based and soft-gelatin products at our facilities.

ALSO READ: 5 Big FDA Decisions Expected in September

According to the filing, Sancilio detailed its strategy as:

Our regulatory strategy is focused on seeking the most efficient pathway for obtaining drug approval while seeking the best available protections for our product candidates. To create our proprietary product candidates, we apply our ALT platform to a combination of lipophilic APIs, each of which is composed of active ingredients already approved by the FDA or active ingredients for which clinical proof of safety or efficacy is available in published literature. As a result, we believe that we are able to utilize the 505(b)(2) New Drug Application, or NDA, regulatory approval pathway.

The company intends to use the proceeds to develop its pipeline, as well as for general corporate purposes.

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.